IFM Investors Pty Ltd boosted its holdings in DexCom, Inc. (NASDAQ: DXCM – Get Rating) by 25.8% during the 1st quarter, HoldingsChannel.com reports. The fund owned 15,857 shares of the medical device company stock after buying an additional 3,256 shares during the period. IFM Investors Pty Ltd’s holdings in DexCom were worth $ 8,112,000 as of its most recent SEC filing.
A number of other hedge funds have also added to or reduced their stakes in DXCM. American National Bank lifted its holdings in shares of DexCom by 33.8% during the 1st quarter. American National Bank now owns 91 shares of the medical device company stock valued at $ 47,000 after buying an additional 23 shares during the period. O Shaughnessy Asset Management LLC lifted its holdings in shares of DexCom by 1.8% during the 4th quarter. O Shaughnessy Asset Management LLC now owns 1,384 shares of the medical device company stock valued at $ 743,000 after buying an additional 25 shares during the period. DAVENPORT & Co LLC lifted its holdings in shares of DexCom by 1.9% during the 4th quarter. DAVENPORT & Co LLC now owns 1,383 shares of the medical device company stock valued at $ 743,000 after buying an additional 26 shares during the period. Quadrant Capital Group LLC lifted its holdings in shares of DexCom by 5.5% during the 4th quarter. Quadrant Capital Group LLC now owns 561 shares of the medical device company stock valued at $ 301,000 after buying an additional 29 shares during the period. Finally, Parkside Financial Bank & Trust lifted its holdings in shares of DexCom by 27.0% during the 4th quarter. Parkside Financial Bank & Trust now owns 141 shares of the medical device company stock valued at $ 75,000 after buying an additional 30 shares during the period. 93.26% of the stock is currently owned by institutional investors and hedge funds.
Several research firms have recently weighed in on DXCM. Canaccord Genuity Group lowered their price target on DexCom from $ 131.25 to $ 125.00 in a report on Friday, April 29th. Raymond James reduced their price objective on DexCom from $ 134.50 to $ 121.50 in a research note on Friday, April 29th. StockNews.com started coverage on DexCom in a research note on Thursday, March 31st. They issued a “hold” rating for the company. Morgan Stanley cut their price target on DexCom to $ 90.75 and set an “equal weight” rating for the company in a research note on Monday, June 13th. Finally, Citigroup cut their price target on DexCom from $ 157.50 to $ 131.25 and set a “buy” rating for the company in a research note on Tuesday, May 17th. Two analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $ 132.75.
Shares of NASDAQ: DXCM opened at $ 77.67 on Monday. The company has a current ratio of 5.27, a quick ratio of 4.79 and a debt-to-equity ratio of 0.90. DexCom, Inc. has a 12 month low of $ 66.89 and a 12 month high of $ 164.86. The company has a 50-day moving average price of $ 93.46 and a 200 day moving average price of $ 108.27. The company has a market cap of $ 30.49 billion, a price-to-earnings ratio of 150.09, a PEG ratio of 3.38 and a beta of 1.08.
DexCom (NASDAQ: DXCM – Get Rating) last announced its quarterly earnings results on Thursday, April 28th. The medical device company reported $ 0.08 EPS for the quarter, missing analysts’ consensus estimates of $ 0.12 by ($ 0.04). DexCom had a net margin of 8.23% and a return on equity of 12.42%. The business had revenue of $ 628.80 million during the quarter, compared to the consensus estimate of $ 623.97 million. During the same period in the previous year, the business posted $ 0.08 EPS. The firm’s revenue was up 24.5% on a year-over-year basis. As a group, equities analysts forecast that DexCom, Inc. will post 0.74 EPS for the current year.
In related news, Director Steven Robert Pacelli sold 250 shares of DexCom stock in a transaction that occurred on Tuesday, May 24th. The shares were sold at an average price of $ 296.33, for a total transaction of $ 74,082.50. Following the transaction, the director now directly owns 35,175 shares of the company stock, valued at $ 10,423,407.75. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Jereme M. Sylvain sold 600 shares of DexCom stock in a transaction that occurred on Monday, June 6th. The shares were sold at an average price of $ 301.57, for a total transaction of $ 180,942.00. Following the transaction, the chief financial officer now directly owns 17,408 shares in the company, valued at $ 5,249,730.56. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 3,759 shares of company stock worth $ 1,571,372. Corporate insiders own 0.41% of the company stock.
DexCom Company Profile: (Get Rating)
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system.
Read More:
Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ: DXCM – Get Rating).
Receive News & Ratings for DexCom Daily: – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for DexCom and related companies with MarketBeat.com’s FREE daily email newsletter.
.